A phase I randomized, double-blind trial of the safety and immunogenicity of FluMist, a live, intranasal influenza virus vaccine versus placebo in immunocompromised children ages 5 through 17 years of age

Trial Profile

A phase I randomized, double-blind trial of the safety and immunogenicity of FluMist, a live, intranasal influenza virus vaccine versus placebo in immunocompromised children ages 5 through 17 years of age

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Influenza virus vaccine live (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 04 May 2009 Status changed from recruiting to completed.
    • 04 May 2009 Status cahnge from recruiting to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top